Tabernanthalog

Tabernanthalog
Clinical data
Other names	TBG; DLX-007; DLX007
Drug class	Non-selective serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor partial agonist
ATC code	None;
Identifiers
	IUPAC name 8-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole;
CAS Number	2483829-59-8;
PubChem CID	146026994;
ChemSpider	114959868;
CompTox Dashboard (EPA)	DTXSID301336754 ;
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.311 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2=C(CC1)NC3=C2C=CC(=C3)OC;
	InChI InChI=1S/C14H18N2O/c1-16-7-5-12-11-4-3-10(17-2)9-14(11)15-13(12)6-8-16/h3-4,9,15H,5-8H2,1-2H3; Key:FNGNYGCPNKZYOG-UHFFFAOYSA-N;

Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure.^[1]^[2] It was developed by David E. Olson and colleagues at the University of California, Davis.^[2] The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders.^[3]^[4]

^ Sharp T, Ippolito A (May 2025). "Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists". Br J Pharmacol. doi:10.1111/bph.70050. PMID 40405723.
^ ^a ^b Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
^ "DLX 7". AdisInsight. 28 May 2025. Retrieved 31 July 2025.
^ Grace B (6 March 2021). "Can we take the high out of psychedelics?". Wired. Retrieved 12 July 2022.